Oruka Therapeutics, Inc.
ORKA
株式のランク
#3289
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
株価
$81.40
時価総額
$5.39B
変化（1日）
1.86%
変化（1年）
205.46%
国
US
取引 Oruka Therapeutics, Inc. (ORKA)
カテゴリー
Healthcare
Oruka Therapeutics, Inc.（ORKA）のP/S比率
2026 時点のP/S比率 TTM: 0
Oruka Therapeutics, Inc. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0 です。2026 年末時点でのP/S比率は 0 でした。
Oruka Therapeutics, Inc. の P/S 比率の履歴（2005 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 2025 | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | -100.00% |
| 2007 | 2.08 | -96.07% |
| 2006 | 52.93 | -91.38% |
| 2005 | 614.26 | 0.00% |
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 41.70 | - |
US
|
|
| 4.19 | - |
AU
|
|
| 10.44 | - |
NL
|
|
| 4.52 | - |
BE
|
